ANX007 targets C1q to inhibit the complement cascade, reducing neuroinflammation and protecting photoreceptors in AMD and GA. The ARCHER trial showed significant vision loss reduction, with a 73% risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback